New combo therapy aims to tackle Hard-to-Treat myeloma
NCT ID NCT07455851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best dose, and see if the combination shrinks tumors better than linvoseltamab alone. About 150 participants will take part, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
REGN17372 (an experimental bispecific antibody) combined with linvoseltamab (another bispecific antibody)
What this could lead to
If successful, this combination could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early (first-in-human) trial, so safety and effectiveness are not yet known. Side effects may occur, and the combination may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Illawarra Cancer care centre, Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Prince of Wales Hospital
RECRUITINGRandwick, New South Wales, 2031, Australia